Non-biological Complex Drugs (NBCDs) are medical compounds that cannot be defined as small molecular, fully identifiable drugs with active pharmaceutical ingredients. They are highly complex and cannot be defined as biologicals as they are not derived from living materials.

NBCD is dedicated to clinical drug development, specializing in osteoarthritis. As a science-driven organization, we have several articles published each year in well respected, peer-reviewed journals.

Non-Biological Complex Drugs (NBCDs) are complex non-biological drugs that comprise large high molecular weight molecules and, often, nanoparticular structures (including liposomes and block-copolymer micelles).

The NBCD working group has the mission to ensure that appropriate science-based approval and post-approval standards are created and globally introduced for NBCDs to ensure patient safety and...

The challenges posed by the development of follow-on versions of NBCD are illustrated in this paper by discussing the ‘families’ of liposomes, iron–carbohydrate (‘iron–sugar’) drugs and glatiramoids.

Nov 23, 2020 · Non-Biological Complex Drugs (NBCDs) are complex non-biological drugs that comprise large high molecular weight molecules and, often, nanoparticular structures (including liposomes and block-copolymer micelles).

The rise of bio- and nano-technology in the last decades has led to the emergence of a new and unique type of medicine known as non-biological complex drugs (NBCDs).

Sep 25, 2013 · The challenges posed by the development of follow-on versions of NBCD are illustrated in this paper by discussing the ‘families’ of liposomes, iron–carbohydrate (‘iron–sugar’) drugs and glatiramoids.

NBCD is known as 'the OA CRO', and is a CRO dedicated to clinical drug development within Osteoarthritis. NBCD specializes in design and execution of clinical trials within both OA pain and DMOAD candidates. They are experts in placebo response mitigation and selecting the right patients for the trials.

Sep 25, 2013 · The challenges posed by the development of follow-on versions of NBCD are illustrated in this paper by discussing the 'families' of liposomes, iron-carbohydrate ('iron-sugar') drugs and...